Linda Rubinstein

Linda Rubinstein serves as a Partner at FLG Partners since September 2010, providing CFO leadership across various companies, from early-stage private firms to billion-dollar public entities. Currently, Linda holds the position of CFO at Adverum Biotechnologies, a public clinical-stage company focused on gene therapy for ocular diseases. Previous roles include Board Member at Biocept, Inc., Consulting CFO at Medikine, Inc. and Sublimity Therapeutics, and Interim CFO at Alector. Linda also provided advisory services during the IPO execution for RenovoRx and held a Senior Financial Advisor role at Apexigen. Linda holds BA and MA degrees in Economics from UCLA.